Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

Abstract Background Capecitabine plus bevacizumab (CAP-B) maintenance treatment after 6 cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOXB) has demonstrated clinical activity and failure to compromise quality of life in patients with metastatic colorectal cancer (MCC) in a previous phase 3...

Full description

Bibliographic Details
Main Authors: Jinsong Su, Jiajie Lai, Ruikun Yang, Bo Xu, Ying Zhu, Mingdong Zhao, Chen Yang, Guanzhao Liang
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Gastroenterology
Subjects:
Capecitabine
Bevacizumab
Colorectal cancer
Progression-free survival
Overall survival
Online Access:http://link.springer.com/article/10.1186/s12876-018-0916-6

Internet

http://link.springer.com/article/10.1186/s12876-018-0916-6

Similar Items